正在加载视频...

视频加载失败

返回首页

#Cybin reports #breakthrough Phase 2 data for #CYB003 in Major Depressive Disorder (#MDD), with 100% of patients responsive to treatment and 71% in remission at 12 months after just two 16mg doses. Learn more: #Neuropsychiatry #MentalHealth #Depression

Helus_Pharma's profile picture

Helus Pharma

9,287 subscribers

11,709 次观看 • 1 年前 •via X (Twitter)

健康养生#Cybin#breakthrough#CYB003#MDD#Neuropsychiatry#MentalHealth#Depression
LIVE

Anya Rossi• Live Now

Private livecam show

9 条评论

Psych Investor 的头像
Psych Investor1 年前

👏👏

SportsFanatic 的头像
SportsFanatic1 年前

Incredible!! Congrats to you and the entire team!!!! 👏🏼👏🏼👏🏼

Dream State Awake 的头像
Dream State Awake1 年前

Big pharma won't like this.

Minimoose 的头像
Minimoose1 年前

Nice! Keep on Moosin' on

Altered Updates 的头像
Altered Updates1 年前

👏

Aurora 的头像
Aurora1 年前

Disappointing to see Cybin partnering with Paul Joseph Watson, who famously said "depression is nothing more than dissatisfaction with life, it's temporary unhappiness." .

B.Smith 的头像
B.Smith1 年前

👌

A Rocket 的头像
A Rocket1 年前

Not so much of a breakthrough when all companies report the same data. No competitive differentiation is possible and all psychedelics substitute for one another. Zero alpha. Returns trend to the mean. Next.

eli.bda 的头像
eli.bda1 年前

Let cybin coooooook

相关视频

We are now enrolling patients as young as 3 in our OCU410ST Phase 2/3 GARDian3 clinical trial for #Stargardtdisease. Phase 1 data shows 100% stabilization or improvement in treated eyes and 48.2% slower lesion growth. Learn more: clinical.request@ocugen.com #OCU410ST #Ocugen
1:02

We are now enrolling patients as young as 3 in our OCU410ST Phase 2/3 GARDian3 clinical trial for #Stargardtdisease. Phase 1 data shows 100% stabilization or improvement in treated eyes and 48.2% slower lesion growth. Learn more: [email protected] #OCU410ST #Ocugen

Ocugen

13,661 次观看 • 9 个月前

More hospitals in England are expected to declare critical incidents as increasing numbers of patients suffering flu and other winter illnesses overwhelm A&E hospitals. Patients at 11 major hospitals are facing a wait of up to 50 hours for treatment. Jonathan Swain reports.
2:32

More hospitals in England are expected to declare critical incidents as increasing numbers of patients suffering flu and other winter illnesses overwhelm A&E hospitals. Patients at 11 major hospitals are facing a wait of up to 50 hours for treatment. Jonathan Swain reports.

Good Morning Britain

24,165 次观看 • 1 年前

100% Cancer Remission Achieved in ALL Patients in Groundbreaking Study Dr. Andrea Cercek, one of the lead researchers, said: “It’s absolutely incredible ... We’ve certainly never seen this before.” All 12 patients experienced complete rectal cancer remission after receiving dostarlimab, a monoclonal antibody. This particular monoclonal antibody achieved 100% cancer remission without chemotherapy, radiation, surgery, or the toxic side effects that come with such therapies. The authors wrote: “All 12 patients (100%; 95% confidence interval) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging ... and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months after treatment). No adverse events of grade 3 or higher have been reported.” How does this monoclonal antibody actually work? Dr. Cercek explained that it essentially unlocks the body’s ability to heal itself.
3:28

100% Cancer Remission Achieved in ALL Patients in Groundbreaking Study Dr. Andrea Cercek, one of the lead researchers, said: “It’s absolutely incredible ... We’ve certainly never seen this before.” All 12 patients experienced complete rectal cancer remission after receiving dostarlimab, a monoclonal antibody. This particular monoclonal antibody achieved 100% cancer remission without chemotherapy, radiation, surgery, or the toxic side effects that come with such therapies. The authors wrote: “All 12 patients (100%; 95% confidence interval) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging ... and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months after treatment). No adverse events of grade 3 or higher have been reported.” How does this monoclonal antibody actually work? Dr. Cercek explained that it essentially unlocks the body’s ability to heal itself.

The Vigilant Fox 🦊

1,600,275 次观看 • 2 年前

100% Cancer Remission Achieved in ALL Patients of Groundbreaking Study Dr. Andrea Cercek, one of the lead researchers, said: “It’s absolutely incredible ... We’ve certainly never seen this before.” All 12 patients experienced complete rectal cancer remission after receiving dostarlimab, a monoclonal antibody. This particular monoclonal antibody achieved 100% cancer remission without chemotherapy, radiation, surgery, or the toxic side effects that come with such therapies. The authors wrote: “All 12 patients (100%; 95% confidence interval) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging ... and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months after treatment). No adverse events of grade 3 or higher have been reported.” How does this monoclonal antibody actually work? Dr. Andrea Cercek explained that it essentially unlocks the body’s ability to heal itself.
3:28

100% Cancer Remission Achieved in ALL Patients of Groundbreaking Study Dr. Andrea Cercek, one of the lead researchers, said: “It’s absolutely incredible ... We’ve certainly never seen this before.” All 12 patients experienced complete rectal cancer remission after receiving dostarlimab, a monoclonal antibody. This particular monoclonal antibody achieved 100% cancer remission without chemotherapy, radiation, surgery, or the toxic side effects that come with such therapies. The authors wrote: “All 12 patients (100%; 95% confidence interval) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging ... and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months after treatment). No adverse events of grade 3 or higher have been reported.” How does this monoclonal antibody actually work? Dr. Andrea Cercek explained that it essentially unlocks the body’s ability to heal itself.

The Vigilant Fox 🦊

2,527,732 次观看 • 2 年前

Psychiatrists aren't curing mental illness. They're managing it. And the stats prove it. - 1 in 5 adults in the US has a mental illness. Treatment rates are up, but so are the numbers. Where are the cures? - Antidepressant use has skyrocketed over 400% in the last two decades. If they were curative, wouldn't we see a corresponding drop in prevalence? Instead, we see long-term dependency. - Remission rates tell the real story: • Only about 1/3 of patients with Major Depressive Disorder achieve remission with their first antidepressant. • After 4 different medication attempts, the remission rate is still dismally low. This isn't to blame dedicated doctors. It's to question a system that's become about lifelong medication management rather than root-cause resolution. We're treating the symptoms, not the disease. We need a paradigm shift. More focus on therapy, lifestyle, community, and trauma-informed care. The goal must be healing, not just maintenance.
1:02

Psychiatrists aren't curing mental illness. They're managing it. And the stats prove it. - 1 in 5 adults in the US has a mental illness. Treatment rates are up, but so are the numbers. Where are the cures? - Antidepressant use has skyrocketed over 400% in the last two decades. If they were curative, wouldn't we see a corresponding drop in prevalence? Instead, we see long-term dependency. - Remission rates tell the real story: • Only about 1/3 of patients with Major Depressive Disorder achieve remission with their first antidepressant. • After 4 different medication attempts, the remission rate is still dismally low. This isn't to blame dedicated doctors. It's to question a system that's become about lifelong medication management rather than root-cause resolution. We're treating the symptoms, not the disease. We need a paradigm shift. More focus on therapy, lifestyle, community, and trauma-informed care. The goal must be healing, not just maintenance.

Camus

19,740 次观看 • 9 个月前

100% Cancer Remission Achieved in ALL Patients in Groundbreaking Study Dr. Andrea Cercek, one of the lead researchers, said: “It’s absolutely incredible ... We’ve certainly never seen this before.” All 12 patients experienced complete rectal cancer remission after receiving dostarlimab, a monoclonal antibody. The authors wrote: “All 12 patients (100%; 95% confidence interval) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging ... and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months after treatment). No adverse events of grade 3 or higher have been reported.” How does this monoclonal antibody actually work? Dr. Andrea Cercek explained that it essentially unlocks the body’s ability to heal itself. Watch the breakdown of this study in the comment below.
2:18

100% Cancer Remission Achieved in ALL Patients in Groundbreaking Study Dr. Andrea Cercek, one of the lead researchers, said: “It’s absolutely incredible ... We’ve certainly never seen this before.” All 12 patients experienced complete rectal cancer remission after receiving dostarlimab, a monoclonal antibody. The authors wrote: “All 12 patients (100%; 95% confidence interval) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging ... and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months after treatment). No adverse events of grade 3 or higher have been reported.” How does this monoclonal antibody actually work? Dr. Andrea Cercek explained that it essentially unlocks the body’s ability to heal itself. Watch the breakdown of this study in the comment below.

The Vigilant Fox 🦊

1,690,044 次观看 • 2 年前

Today, we announced the completion of enrollment in our global BROADEN2 Phase 2b trial of KT-621, our investigational, first-in-class, oral STAT6 degrader, in atopic dermatitis, nearly six months ahead of anticipated timelines. This milestone enables us to accelerate our expected topline data readout to year-end 2026 and continue advancing KT-621 as a potential oral treatment option for patients living with atopic dermatitis and other Type 2 inflammatory diseases. Read more in our press release:
0:45

Today, we announced the completion of enrollment in our global BROADEN2 Phase 2b trial of KT-621, our investigational, first-in-class, oral STAT6 degrader, in atopic dermatitis, nearly six months ahead of anticipated timelines. This milestone enables us to accelerate our expected topline data readout to year-end 2026 and continue advancing KT-621 as a potential oral treatment option for patients living with atopic dermatitis and other Type 2 inflammatory diseases. Read more in our press release:

Kymera Therapeutics

20,788 次观看 • 1 个月前

B-Well 1 and B-Well 2: In two phase 3 trials, 19% of patients with chronic hepatitis B infection had a functional cure with the antisense oligonucleotide bepirovirsen, 24 weeks after stopping all HBV treatment; functional cure was not seen with placebo. Full results and Research Summary:
1:32

B-Well 1 and B-Well 2: In two phase 3 trials, 19% of patients with chronic hepatitis B infection had a functional cure with the antisense oligonucleotide bepirovirsen, 24 weeks after stopping all HBV treatment; functional cure was not seen with placebo. Full results and Research Summary:

NEJM

15,827 次观看 • 1 个月前

Today we’re reporting interim Phase 1 clinical data for our REC-617 monotherapy trial – with plans to expand into combination studies in advanced solid tumors. At the AACR Special Conference in Cancer Research, CSO David Hallett shared interim monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. 🔹The interim Phase 1 clinical data for REC-617 included: ▫️Dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target engagement; ▫️Confirmed partial response (PR) during monotherapy dose-escalation in a patient with platinum-resistant ovarian cancer, treated with 4 lines of prior therapy in an advanced setting, with durable response ongoing after more than 6 months of treatment; ▫️In 4 additional patients, a best response of stable disease (SD) for up to 6 months of treatment. Dr. Hallett noted: “Cell cycle dysregulation and transcriptional 'addiction' are both hallmarks of many aggressive cancers. By inhibiting CDK7, we have the potential to target both mechanisms while fine tuning the therapeutic index.” "These initial findings for REC-617 represent an exciting step forward in the development of CDK7 inhibitors, with a favorable PK/PD profile and a durable confirmed partial response observed in dose escalation in a highly pre-treated patient population," said Najat Khan, Ph.D., Chief R&D Officer and Chief Commercial Officer. “Designed using our AI-powered OS platform, REC-617 reflects our focus on enhancing the therapeutic index to deliver more effective and safer treatment options for patients. We are eager to continue this momentum in dose escalation and to initiate the next phase of the program next year." 👉Learn more: 🔹Join the Update Call: Tomorrow, Tues., Dec. 10 at 8:30am ET, Dr. Hallett and Dr. Khan will hold a live Update Call webcast to present the preliminary data. ▫️Submit questions for the Update Call here: ▫️Tune in to the Update Call here on X or on: LinkedIn: YouTube:
0:20

Today we’re reporting interim Phase 1 clinical data for our REC-617 monotherapy trial – with plans to expand into combination studies in advanced solid tumors. At the AACR Special Conference in Cancer Research, CSO David Hallett shared interim monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. 🔹The interim Phase 1 clinical data for REC-617 included: ▫️Dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target engagement; ▫️Confirmed partial response (PR) during monotherapy dose-escalation in a patient with platinum-resistant ovarian cancer, treated with 4 lines of prior therapy in an advanced setting, with durable response ongoing after more than 6 months of treatment; ▫️In 4 additional patients, a best response of stable disease (SD) for up to 6 months of treatment. Dr. Hallett noted: “Cell cycle dysregulation and transcriptional 'addiction' are both hallmarks of many aggressive cancers. By inhibiting CDK7, we have the potential to target both mechanisms while fine tuning the therapeutic index.” "These initial findings for REC-617 represent an exciting step forward in the development of CDK7 inhibitors, with a favorable PK/PD profile and a durable confirmed partial response observed in dose escalation in a highly pre-treated patient population," said Najat Khan, Ph.D., Chief R&D Officer and Chief Commercial Officer. “Designed using our AI-powered OS platform, REC-617 reflects our focus on enhancing the therapeutic index to deliver more effective and safer treatment options for patients. We are eager to continue this momentum in dose escalation and to initiate the next phase of the program next year." 👉Learn more: 🔹Join the Update Call: Tomorrow, Tues., Dec. 10 at 8:30am ET, Dr. Hallett and Dr. Khan will hold a live Update Call webcast to present the preliminary data. ▫️Submit questions for the Update Call here: ▫️Tune in to the Update Call here on X or on: LinkedIn: YouTube:

Recursion

11,887 次观看 • 1 年前

New Research: Ketogenic Diet Associated with Improvements in Depression in College Students The first ever peer-reviewed pilot trial of ketogenic diet for depression was published today in Translational Psychiatry. The study was conducted in college students with a primary diagnosis of major depressive disorder at The Ohio State University. All 16 students who completed the study saw improvements in depression, with an average reduction in symptoms of 70% across scales. Metabolic health markers also improved. The video below includes perspectives from the research team and students who participated in the study. Read the full study in Translational Psychiatry: Read Ohio State News announcement:
5:05

New Research: Ketogenic Diet Associated with Improvements in Depression in College Students The first ever peer-reviewed pilot trial of ketogenic diet for depression was published today in Translational Psychiatry. The study was conducted in college students with a primary diagnosis of major depressive disorder at The Ohio State University. All 16 students who completed the study saw improvements in depression, with an average reduction in symptoms of 70% across scales. Metabolic health markers also improved. The video below includes perspectives from the research team and students who participated in the study. Read the full study in Translational Psychiatry: Read Ohio State News announcement:

Metabolic Mind

82,360 次观看 • 10 个月前

BCG+mitomycin vs BCG alone in BCG-naïve NMIBC — the ANZUP 1301 phase 3 trial (n=501) 🟰Not superior on DFS (75% vs 71% at 2 yr) 🥴 But the combination used 39% ⬇️BCG doses (median 9 vs 16) & more patients completed their planned treatment (78% vs 68%) In a 🌐of ongoing BCG shortages 🟰 outcomes with substantially less BCG is a practical win European Urology European Association of Urology (EAU) European Association of Urology (EAU)ESU
1:24

BCG+mitomycin vs BCG alone in BCG-naïve NMIBC — the ANZUP 1301 phase 3 trial (n=501) 🟰Not superior on DFS (75% vs 71% at 2 yr) 🥴 But the combination used 39% ⬇️BCG doses (median 9 vs 16) & more patients completed their planned treatment (78% vs 68%) In a 🌐of ongoing BCG shortages 🟰 outcomes with substantially less BCG is a practical win European Urology European Association of Urology (EAU) European Association of Urology (EAU)ESU

Laura Bukavina

10,595 次观看 • 24 天前

Considering ketogenic therapy for bipolar disorder or other serious mental illnesses? This powerful story from Shannon Harwood shows how ketogenic therapy helped her achieve full remission from bipolar 2 disorder after 35 years of recurring episodes, failed medications, and misdiagnoses. In this video, Shannon shares her personal journey: from undiagnosed symptoms in her teens, to years of misdiagnosis and ineffective treatments, to discovering ketogenic therapy at age 48. Within just five days of starting, she experienced a dramatic shift in her mental clarity, energy, and overall functioning. You'll hear: - How bipolar 2 disorder often goes undiagnosed or misdiagnosed as major depression - The impact of living with unrelenting depressive episodes for decades - How medications helped—but also introduced serious side effects - Why she turned to ketogenic therapy and how it changed everything - What it means to find root cause healing instead of just symptom management Shannon is now off all psychiatric medications and has remained symptom-free for years. Her story is one of hope, resilience, and the possibility of full recovery. If you or someone you love is navigating severe mental illness and looking for new options, this is a must-watch. #MetabolicHealth #KetogenicTherapy #BipolarDisorder #MentalHealthRecovery #MetabolicMind #Bipolar2 #HealingIsPossible #NutritionAndMentalHealth #RootCauseHealing Resources Mentioned: - Get better acquainted with Shannon’s mental health strategies at her THINK+SMART profile: - Learn more about the THINK+SMART framework: a self-guided, community-based framework that helps you develop a customized metabolic approach to mental health: Follow our channel for more information and education from Bret Scher, MD, FACC, including interviews with leading experts in Metabolic Psychiatry. Learn more about metabolic psychiatry and find helpful resources at
11:18

Considering ketogenic therapy for bipolar disorder or other serious mental illnesses? This powerful story from Shannon Harwood shows how ketogenic therapy helped her achieve full remission from bipolar 2 disorder after 35 years of recurring episodes, failed medications, and misdiagnoses. In this video, Shannon shares her personal journey: from undiagnosed symptoms in her teens, to years of misdiagnosis and ineffective treatments, to discovering ketogenic therapy at age 48. Within just five days of starting, she experienced a dramatic shift in her mental clarity, energy, and overall functioning. You'll hear: - How bipolar 2 disorder often goes undiagnosed or misdiagnosed as major depression - The impact of living with unrelenting depressive episodes for decades - How medications helped—but also introduced serious side effects - Why she turned to ketogenic therapy and how it changed everything - What it means to find root cause healing instead of just symptom management Shannon is now off all psychiatric medications and has remained symptom-free for years. Her story is one of hope, resilience, and the possibility of full recovery. If you or someone you love is navigating severe mental illness and looking for new options, this is a must-watch. #MetabolicHealth #KetogenicTherapy #BipolarDisorder #MentalHealthRecovery #MetabolicMind #Bipolar2 #HealingIsPossible #NutritionAndMentalHealth #RootCauseHealing Resources Mentioned: - Get better acquainted with Shannon’s mental health strategies at her THINK+SMART profile: - Learn more about the THINK+SMART framework: a self-guided, community-based framework that helps you develop a customized metabolic approach to mental health: Follow our channel for more information and education from Bret Scher, MD, FACC, including interviews with leading experts in Metabolic Psychiatry. Learn more about metabolic psychiatry and find helpful resources at

Metabolic Mind

55,537 次观看 • 1 年前

Dr. Patrick Soon-Shiong shows stunning brain tumor remission with new treatment Patients who failed chemo, radiation, and surgery achieved complete responses—no chemo, no radiation. Before/after scans: Tumor shrinking dramatically in months. "Very impressive as a visual representation." Hope for those who've run out of options. 0:43 clip inside—powerful evidence.
0:43

Dr. Patrick Soon-Shiong shows stunning brain tumor remission with new treatment Patients who failed chemo, radiation, and surgery achieved complete responses—no chemo, no radiation. Before/after scans: Tumor shrinking dramatically in months. "Very impressive as a visual representation." Hope for those who've run out of options. 0:43 clip inside—powerful evidence.

Camus

112,621 次观看 • 7 个月前

Shocking results, hope restored for cancer patients. Cancer vanished in 100% of the patients, after 6 months trial with a drug, dostarlimab, with no significant side effects, first time in history of cancer. Colorectal/rectal cancer the 5th commonest cancer in Africa, and usually by the time its diagnosed it would have spread throughout the body giving low survival rates with the traditional treatment.
3:23

Shocking results, hope restored for cancer patients. Cancer vanished in 100% of the patients, after 6 months trial with a drug, dostarlimab, with no significant side effects, first time in history of cancer. Colorectal/rectal cancer the 5th commonest cancer in Africa, and usually by the time its diagnosed it would have spread throughout the body giving low survival rates with the traditional treatment.

Dr. Misheck Ruwende

107,404 次观看 • 3 年前

On the path to EIS in 2025, a major step has just been taken with an 8-week test campaign with the future Deutsche Marine #NH90 Sea Tiger. For the next 2 months, a 🚁 will be deployed from Nordholz in a full demo of its capabilities. Learn more:
1:38

On the path to EIS in 2025, a major step has just been taken with an 8-week test campaign with the future Deutsche Marine #NH90 Sea Tiger. For the next 2 months, a 🚁 will be deployed from Nordholz in a full demo of its capabilities. Learn more:

Airbus Helicopters

20,635 次观看 • 2 年前

People with mental health problems are sometimes waiting days for treatment in A&E, something nurses say is ‘degrading’, ‘distressing’ and in some cases ‘akin to torture’. The nursing union, the RCN says waits of over 12 hours have increased fivefold in 6 years for mental health patients. Jonathan Swain reports.
2:15

People with mental health problems are sometimes waiting days for treatment in A&E, something nurses say is ‘degrading’, ‘distressing’ and in some cases ‘akin to torture’. The nursing union, the RCN says waits of over 12 hours have increased fivefold in 6 years for mental health patients. Jonathan Swain reports.

Good Morning Britain

17,322 次观看 • 1 年前

The ketogenic diet is powerful brain medicine. Consider these observations from a study I co-authored, conducted by my friend Dr. Albert Danan, a psychiatrist practicing in Toulouse, France. 31 adults with "treatment-resistant" schizophrenia, bipolar disorder, or major depression volunteered to try a mildly #ketogenic whole-foods diet in the hospital, under close medical and psychiatric supervision. ✨ All 28 patients who stayed on the diet for more than two weeks experienced substantial improvements in mental and physical health ✨ 43% achieved complete clinical remission from their psychiatric condition ✨ 64% left the hospital on less psychiatric medication ✨ Their general metabolic health also improved dramatically You do not see outcomes like this in conventional inpatient psychiatric care. View the study:
1:04

The ketogenic diet is powerful brain medicine. Consider these observations from a study I co-authored, conducted by my friend Dr. Albert Danan, a psychiatrist practicing in Toulouse, France. 31 adults with "treatment-resistant" schizophrenia, bipolar disorder, or major depression volunteered to try a mildly #ketogenic whole-foods diet in the hospital, under close medical and psychiatric supervision. ✨ All 28 patients who stayed on the diet for more than two weeks experienced substantial improvements in mental and physical health ✨ 43% achieved complete clinical remission from their psychiatric condition ✨ 64% left the hospital on less psychiatric medication ✨ Their general metabolic health also improved dramatically You do not see outcomes like this in conventional inpatient psychiatric care. View the study:

Georgia Ede MD

42,247 次观看 • 2 年前

Breakthrough Update: Today, Vertex announced that they are beginning their Phase 3, or pivotal trial for VX-880, a stem cell-derived islet therapy. A pivotal trial gathers the data required for an FDA submission. This therapy is for people with type 1 diabetes (T1D) and hypoglycemia unawareness and severe hypoglycemic episodes. This is a HUGE first for the #T1D community as it is the first time a scalable cure for some people with T1D is entering this phase. Breakthrough T1D and the T1D Fund are incredibly proud to have supported this work in cell therapies—a top priority for our organization. We want to congratulate our partners at Vertex and thank all the patients who have participated in clinical trials. Your courage and commitment are inspiring. Learn more here:
1:29

Breakthrough Update: Today, Vertex announced that they are beginning their Phase 3, or pivotal trial for VX-880, a stem cell-derived islet therapy. A pivotal trial gathers the data required for an FDA submission. This therapy is for people with type 1 diabetes (T1D) and hypoglycemia unawareness and severe hypoglycemic episodes. This is a HUGE first for the #T1D community as it is the first time a scalable cure for some people with T1D is entering this phase. Breakthrough T1D and the T1D Fund are incredibly proud to have supported this work in cell therapies—a top priority for our organization. We want to congratulate our partners at Vertex and thank all the patients who have participated in clinical trials. Your courage and commitment are inspiring. Learn more here:

Breakthrough T1D

42,485 次观看 • 1 年前